A new amido-bridged nucleic acid (AmNA)-modified ASO has been recently developed that downregulates SNCA mRNA and protein levels in in vitro and in vivo PD models finally leading to improved neurological deficits [65]. Here, SNCA is linked to Parkinson disease.